Corvus Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Corvus Pharmaceuticals, Inc. (CRVS) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$17.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$17.96M.
- Corvus Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$13.69M.
- Corvus Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$12.32M.
- Corvus Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$10.16M.
- Corvus Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$42.42M.
- Corvus Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$62.29M.
- Corvus Pharmaceuticals, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$27.03M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.96M 10-Q · filed 2026-08-06 | -$31.65M 10-Q · filed 2026-08-06 | -$43.97M derived: sum of 3 quarters · filed 2026-08-06 | -$54.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$13.69M 10-Q · filed 2026-05-07 | -$26.01M derived: sum of 2 quarters · filed 2026-05-07 | -$36.17M derived: sum of 3 quarters · filed 2026-05-07 | -$44.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$12.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$22.48M derived: sum of 2 quarters · filed 2026-03-12 | -$30.48M derived: sum of 3 quarters · filed 2026-08-06 | -$42.42M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$10.16M 10-Q · filed 2025-11-04 | -$18.16M derived: sum of 2 quarters · filed 2026-08-06 | -$30.10M 10-Q · filed 2025-11-04 | -$40.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$8.00M 10-Q · filed 2026-08-06 | -$19.95M 10-Q · filed 2026-08-06 | -$30.05M derived: sum of 3 quarters · filed 2026-08-06 | -$70.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$9.94M 10-Q · filed 2026-05-07 | -$22.05M derived: sum of 2 quarters · filed 2026-05-07 | -$62.27M derived: sum of 3 quarters · filed 2026-05-07 | -$66.53M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$12.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$52.33M derived: sum of 2 quarters · filed 2026-03-12 | -$56.59M derived: sum of 3 quarters · filed 2026-03-12 | -$62.29M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$40.22M 10-Q · filed 2025-11-04 | -$44.48M derived: sum of 2 quarters · filed 2025-11-04 | -$50.18M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$4.26M 10-Q · filed 2025-08-07 | -$9.96M 10-Q · filed 2025-08-07 | ||
| 2023-12-31 | -$27.03M 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |